Melanoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (12/21/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Melanoma

Editorial changes were made to this section.

Stage Information for Melanoma

Updated staging information for 2016 (cited American Joint Committee on Cancer as reference 1).

Resectable Stage III Melanoma Treatment

This section was extensively revised.

Unresectable Stage III, Stage IV, and Recurrent Melanoma Treatment

Added a list item about an assessment of a change in the dosing regimen for nivolumab in metastatic melanoma (cited Zhao et al. as reference 5).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Unresectable Stage III, Stage IV, and Recurrent Melanoma Treatment

Next section >
About This PDQ Summary